Who Exports Amiodarone from India — 243 Suppliers Behind a $74.6M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for pharmaceutical manufacturing, particularly in active pharmaceutical ingredients (APIs). The city's well-established infrastructure and supportive regulatory environment have attracted numerous pharmaceutical companies specializing in API production. While specific data on Amiodarone API production in Hyderabad is not detailed in the provided dataset, the city's prominence in bulk drug manufacturing suggests a significant role in the supply chain for such medications.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Companies like Zydus Lifesciences Limited, headquartered in Ahmedabad, are key players in this region. Zydus Lifesciences, formerly known as Cadila Healthcare Limited, is a major exporter of Amiodarone, contributing $2.3 million (3.0%) to the total exports. The region's emphasis on finished dosage forms complements the API production from other clusters, ensuring a seamless supply chain for medications like Amiodarone.

The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. Companies such as UNICHEM LABORATORIES LIMITED, based in Mumbai, lead in Amiodarone exports, accounting for $37.2 million (49.8%) of the total. The region's strategic location, coupled with robust port facilities, facilitates efficient international distribution, particularly to major markets like the United States, which receives 82.9% of India's Amiodarone exports.

Baddi-Nalagarh in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives. The area hosts numerous pharmaceutical companies, contributing to its status as Asia's largest pharmaceutical hub. While specific figures for Amiodarone production in this cluster are not provided, the region's overall manufacturing capacity suggests a potential role in the production and supply of such medications.

• Diversify Supplier Base: Given that the top two exporters—UNICHEM LABORATORIES LIMITED and RUBICON RESEARCH PRIVATE LIMITED—account for 77.8% of Amiodarone exports, it's advisable to engage with multiple suppliers to mitigate risks associated with over-reliance on a limited number of sources.

• Leverage Regional Strengths: Utilize the API production capabilities of Hyderabad and the formulation expertise of the Ahmedabad-Vadodara corridor to optimize the supply chain for Amiodarone.

• Optimize Logistics: Capitalize on the export infrastructure of the Mumbai-Thane-Raigad region to ensure efficient distribution, especially to key markets like the United States.

• Monitor Regulatory Compliance: Ensure that all suppliers adhere to international quality standards and regulatory requirements, particularly when exporting to stringent markets such as the United States and the European Union.

By strategically engaging with these pharmaceutical clusters and adhering to these recommendations, stakeholders can enhance the resilience and efficiency of the Amiodarone supply chain.